A new daily tablet for endometriosis, called linzagolix (also known as Yselty), has been approved for use on the NHS and is ...

Around 1,000 women in England a year with endometriosis will soon have access to the first daily oral therapy after Gedeon Richter's Ryeqo was cleared for NHS use. This morning, NICE recommended ...

Ryeqo was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) last October based on results from the LIBERTY programme, consisting of two 24-week phase 3 clinical trials.

Media coverage of endometriosis shows a clear pattern. The disease, which manifests with uterus lining-like tissue growing elsewhere in the body, has for a long time suffered from a lack of viable ...

A new at-home daily pill for endometriosis has been approved for use on the NHS in England. The tablet, called linzagolix but ...

known as relugolix combination therapy or Ryeqo. Helen Knight, director of medicines evaluation at Nice, said: “We’re pleased to recommend linzagolix as a new treatment option for endometriosis. As a ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

This approval follows Nice's sanctioning of the first long-term daily pill for endometriosis in March, known as relugolix combination therapy or Ryeqo. Helen Knight, director of medicines ...

A new at-home treatment option offers hope for women suffering from endometriosis. The NHS has approved linzagolix, also known as Yselty, a once-daily pill designed to alleviate the debilitating ...

The news comes after Nice approved the first long-term daily pill for endometriosis in March, known as relugolix combination therapy or Ryeqo. Helen Knight, director of medicines evaluation at Nic ...